Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

Last Close
Jun 17 04:00PM ET
34.56
Dollar change
-0.54
Percentage change
-1.54
%
Index- P/E14.09 EPS (ttm)2.45 Insider Own21.15% Shs Outstand425.59M Perf Week2.92%
Market Cap19.43B Forward P/E6.87 EPS next Y5.03 Insider Trans0.00% Shs Float332.24M Perf Month1.59%
Income1.09B PEG1.31 EPS next Q1.05 Inst Own77.21% Short Float8.73% Perf Quarter3.44%
Sales2.26B P/S8.58 EPS this Y6.93% Inst Trans1.94% Short Ratio5.50 Perf Half Y37.09%
Book/sh15.72 P/B2.20 EPS next Y13.89% ROA6.48% Short Interest29.02M Perf Year27.06%
Cash/sh1.96 P/C17.67 EPS next 5Y10.77% ROE16.57% 52W Range24.05 - 35.38 Perf YTD35.48%
Dividend Est.0.91 (2.65%) P/FCF7.05 EPS past 5Y-21.51% ROIC8.21% 52W High-2.32% Beta0.47
Dividend TTM0.86 (2.49%) Quick Ratio1.56 Sales past 5Y4.52% Gross Margin- 52W Low43.70% ATR (14)0.69
Dividend Ex-DateMay 16, 2025 Current Ratio1.56 EPS Y/Y TTM37.75% Oper. Margin83.91% RSI (14)59.70 Volatility2.33% 1.44%
Employees99 Debt/Eq1.14 Sales Y/Y TTM1.15% Profit Margin48.24% Recom1.57 Target Price42.17
Option/ShortYes / Yes LT Debt/Eq0.99 EPS Q/Q5042.45% Payout43.94% Rel Volume0.56 Prev Close35.10
Sales Surprise18.95% EPS Surprise-56.79% Sales Q/Q0.05% EarningsMay 08 BMO Avg Volume5.27M Price34.56
SMA203.19% SMA505.09% SMA20015.40% Trades Volume5,922,785 Change-1.54%
Date Action Analyst Rating Change Price Target Change
May-16-25Initiated Morgan Stanley Overweight $51
Jun-03-24Downgrade UBS Buy → Neutral $28
Jun-14-22Resumed UBS Buy $47
May-13-22Initiated Scotiabank Sector Outperform $53
Apr-27-22Initiated Goldman Buy $56
Apr-14-22Upgrade JP Morgan Neutral → Overweight $50
Apr-06-22Resumed Morgan Stanley Overweight $48
Oct-29-21Upgrade Citigroup Neutral → Buy $50
Jul-30-21Initiated Tigress Financial Buy $50
Nov-09-20Upgrade UBS Neutral → Buy $52 → $51
Jun-12-25 07:26PM
Jun-09-25 09:54AM
Jun-04-25 04:15PM
May-16-25 04:30PM
May-13-25 08:15AM
04:15PM Loading…
May-12-25 04:15PM
May-08-25 08:03PM
10:30AM
08:25AM
07:15AM
May-07-25 12:34PM
May-05-25 09:15AM
May-01-25 10:01AM
Apr-28-25 06:50PM
Apr-24-25 08:16AM
07:36AM Loading…
07:36AM
Apr-22-25 12:00PM
11:20AM
Apr-21-25 04:15PM
Apr-17-25 04:15PM
Apr-10-25 06:20AM
Apr-08-25 04:15PM
Apr-02-25 09:47AM
Apr-01-25 10:00AM
06:20AM
Mar-29-25 07:15AM
Mar-27-25 08:15AM
Mar-26-25 11:43AM
Mar-25-25 09:19PM
Mar-21-25 11:30AM
05:12AM Loading…
05:12AM
Feb-27-25 04:15PM
Feb-23-25 03:03PM
Feb-13-25 07:57PM
Feb-12-25 09:06AM
06:30AM
02:07AM
Feb-11-25 07:33AM
07:15AM
Feb-10-25 08:03AM
Jan-29-25 09:00AM
Jan-28-25 04:15PM
Jan-23-25 06:29AM
Jan-15-25 01:52PM
Jan-12-25 11:24AM
Jan-11-25 01:10PM
Jan-10-25 07:30AM
07:15AM
Jan-09-25 04:15PM
Dec-27-24 05:47AM
Dec-24-24 04:45AM
Dec-19-24 08:06PM
Nov-27-24 04:15PM
11:11AM
Nov-14-24 04:30PM
Nov-07-24 07:10AM
02:10AM
12:08AM
Nov-06-24 07:16PM
07:15AM
Nov-04-24 04:15PM
04:01PM
Nov-03-24 06:11AM
Oct-16-24 04:15PM
Oct-11-24 08:15AM
Oct-09-24 05:31PM
03:50PM
Sep-03-24 05:14PM
05:06PM
Aug-28-24 04:15PM
Aug-26-24 06:16AM
Aug-23-24 05:32AM
Aug-17-24 03:58PM
Aug-16-24 06:09PM
Aug-09-24 01:05AM
Aug-08-24 04:16PM
07:00AM
Jul-24-24 08:30AM
Jul-19-24 08:15AM
Jul-17-24 04:15PM
Jul-15-24 12:10PM
Jul-02-24 07:44PM
06:58PM
Jun-26-24 06:00AM
Jun-24-24 12:56PM
Jun-05-24 06:14AM
Jun-04-24 04:15PM
Jun-03-24 05:15PM
May-28-24 07:10AM
May-27-24 06:28PM
May-25-24 11:10PM
May-22-24 04:10PM
04:00PM
May-20-24 02:41PM
May-13-24 08:15AM
May-10-24 01:07AM
May-09-24 03:35PM
12:00PM
11:56AM
10:46AM
Royalty Pharma Plc engages in the provision of drug development services. It operates as a funder of innovation across the biopharmaceutical industry, collaborating with innovators from academic institutions, research hospitals and not-for-profits through small and mid-cap biotechnology companies to global pharmaceutical companies. Its portfolio includes royalties, including AbbVie and J&J's Imbruvica, Astellas and Pfizer's Xtandi, Biogen's Tysabri, Gilead's HIV franchise, Merck's Januvia, Novartis' Promacta, Vertex's Kalydeco, Orkambi, Symdeko and Trikafta, and five development-stage product candidates. The company was founded by Pablo Gerardo Legorreta and Rory B. Riggs in 1996 and is headquartered in New York, NY.